C WorldWide Group Holding A S boosted its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 33.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 75,431 shares of the biotechnology company’s stock after purchasing an additional 18,919 shares during the period. C WorldWide Group Holding A S’s holdings in BioMarin Pharmaceutical were worth $7,315,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. Nissay Asset Management Corp Japan ADV grew its holdings in BioMarin Pharmaceutical by 4.8% during the 2nd quarter. Nissay Asset Management Corp Japan ADV now owns 12,078 shares of the biotechnology company’s stock valued at $1,138,000 after purchasing an additional 556 shares during the last quarter. Scout Investments Inc. grew its holdings in BioMarin Pharmaceutical by 125.6% during the 2nd quarter. Scout Investments Inc. now owns 214,099 shares of the biotechnology company’s stock valued at $20,168,000 after purchasing an additional 119,185 shares during the last quarter. Waddell & Reed Financial Inc. grew its holdings in BioMarin Pharmaceutical by 5.0% during the 2nd quarter. Waddell & Reed Financial Inc. now owns 3,337,346 shares of the biotechnology company’s stock valued at $314,378,000 after purchasing an additional 160,247 shares during the last quarter. Gideon Capital Advisors Inc. bought a new position in BioMarin Pharmaceutical in the 2nd quarter worth about $411,000. Finally, Worldquant Millennium Quantitative Strategies LLC bought a new position in BioMarin Pharmaceutical in the 2nd quarter worth about $13,166,000.
In other news, Director Alan Lewis sold 4,200 shares of the company’s stock in a transaction that occurred on Tuesday, August 21st. The shares were sold at an average price of $100.09, for a total value of $420,378.00. Following the completion of the sale, the director now owns 21,160 shares of the company’s stock, valued at approximately $2,117,904.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Elaine J. Heron sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 5th. The stock was sold at an average price of $96.94, for a total transaction of $96,940.00. Following the completion of the sale, the director now directly owns 41,685 shares of the company’s stock, valued at approximately $4,040,943.90. The disclosure for this sale can be found here. Insiders sold a total of 69,850 shares of company stock valued at $6,911,128 in the last ninety days. Corporate insiders own 1.90% of the company’s stock.
A number of brokerages have commented on BMRN. Cantor Fitzgerald set a $126.00 target price on shares of BioMarin Pharmaceutical and gave the stock a “buy” rating in a research note on Sunday. BidaskClub upgraded shares of BioMarin Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Saturday, July 14th. ValuEngine upgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Thursday, July 12th. Raymond James upped their target price on shares of BioMarin Pharmaceutical from $113.00 to $114.00 and gave the stock a “buy” rating in a research note on Friday, October 26th. Finally, Stifel Nicolaus upped their target price on shares of BioMarin Pharmaceutical from $102.00 to $109.00 and gave the stock a “buy” rating in a research note on Friday, August 3rd. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $117.00.
Shares of BMRN opened at $96.58 on Wednesday. BioMarin Pharmaceutical Inc. has a fifty-two week low of $75.81 and a fifty-two week high of $106.74. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.26 and a current ratio of 2.87.
BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Thursday, October 25th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.15. BioMarin Pharmaceutical had a negative net margin of 8.35% and a negative return on equity of 2.98%. The firm had revenue of $391.71 million during the quarter, compared to analysts’ expectations of $369.43 million. As a group, analysts anticipate that BioMarin Pharmaceutical Inc. will post -0.14 EPS for the current fiscal year.
WARNING: This article was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/11/07/c-worldwide-group-holding-a-s-has-7-32-million-position-in-biomarin-pharmaceutical-inc-bmrn.html.
BioMarin Pharmaceutical Profile
BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.
Featured Story: Return on Investment (ROI) Defined, Explained
Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.